Titlebook: Nasal Polyposis and its Management; Pathogenesis, Medica ?zlem ?nerci Celebi,T. Metin ?nerci Book 2024Latest edition Springer Nature Switze

亂砍

bizarre

AVERT

Biofilms in Chronic Rhinosinusitis,hat planktonic bacteria demonstrate. Biofilm-forming bacteria are common. Bacterial biofilms may contribute to medically recalcitrant chronic rhinosinusitis (CRS). Tactics developed to treat planktonic bacteria are ineffective against bacteria in a biofilm—this helps explain a portion of the persist

anaphylaxis

Treatment of Nasal Polyposis with Biologics,filtration. A substantial proportion of severe CRSwNP patients, typically with a high degree of type 2 inflammation, continues to have bothersome symptoms, despite currently available medical treatment and/or sinus surgery. For these difficult-to-treat patients, biologics targeting key mediators of

AER

The Impact of the Microbiome in Chronic Rhinosinusitis with Nasal Polyps,lthy and pathologic states. Chronic rhinosinusitis with nasal polyposis is a complex and heterogeneous disease process that is characterized by distinct microbiome perturbations. These include decreased overall diversity, an increased relative abundance of organisms such as ., ., ., and decreased re

WAG

, Superantigens, and Nasal Polyps,hanisms, biofilm formation, and epithelial barrier dysfunction. . enterotoxins act as superantigens resulting in excessive and uncoordinated immune responses in some nasal polyp patients. Superantigens directly activate T cells by binding MCH class II and T-cell receptor molecules and elicit an immu

使習(xí)慣于

Fungal-Induced Inflammation and Nasal Polyps,n of cytokines by epithelial cells (IL-33), inducing lymphocytes to release IL-13 and IL-5, which are crucial for the eosinophilic inflammation, occurring only in CRS patients but not in healthy controls. Preceding fungi induce an eosinophilic tissue airway inflammation and resulting nasal obstructi

樸素

使迷醉

Endotyping of Nasal Polyposis,l guidelines. These include the allergic variant known as central compartment atopic sinus disease (CCAD), adult-onset eosinophilic chronic rhinosinusitis (eCRS), and a non-eosinophilic CRS (non-eCRS) subtype. These phenotypes necessitate distinct treatment strategies, and the underlying molecular p

Type-1-Diabetes